Creating advanced CAR T cells to fight HIV
Developing potent HIV-specific CAR T cells through optimizing antigen sensitivity
This study is testing a new type of treatment using specially designed immune cells to help people with HIV by making them better at finding and fighting HIV-infected cells, which could lead to improved health without just relying on standard medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11110422 on NIH RePORTER |
What this research studies
This research focuses on developing genetically engineered CAR T cells that specifically target HIV. By enhancing the sensitivity of these cells to recognize and attack HIV-infected cells, the goal is to improve their effectiveness in reducing viral loads and preventing the loss of immune cells. The approach involves optimizing the design of CAR T cells to ensure they can effectively respond to low levels of HIV antigens, which is crucial for successful treatment. Patients may benefit from a novel therapy that could potentially lead to better management of HIV without relying solely on antiretroviral drugs.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals living with HIV who are seeking alternative treatment options beyond standard antiretroviral therapy.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS with significant immune system damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for HIV, potentially reducing the need for lifelong antiretroviral therapy.
How similar studies have performed: Previous research has shown promising results with CAR T cell therapies in treating blood cancers, suggesting potential for success in targeting HIV as well.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Claiborne, Daniel Thomas — Wistar Institute
- Study coordinator: Claiborne, Daniel Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.